Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Law Firms
Life Sciences
High-Tech
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report ASOs, gene therapy, and small molecules in the DMD drug pipeline: patent landscape, key assignees, and emerging modalities from exon-skipping to AAV microdystrophin.
Article | Report How optical neural networks use photonic chips to slash AI training energy costs — from 10 mW phase modulators to terabit-per-second weight encoding.
Article | Report Mapping the 2026 solid-state electrolyte patent landscape: oxide, sulfide, polymer, and composite SSE clusters, key assignees, and five emerging directions shaping next-gen batteries.
Article | Report Mapping the 2026 solid-state electrolyte patent landscape: material families, key assignees, emerging architectures, and strategic IP implications for ASSB development.
Article | Report A 2026 patent landscape of implantable neural interface technology: electrode materials, wireless power, closed-loop stimulation, and BCI signal processing trends.
Article | Report How does Intel's RibbonFET compare to TSMC's GAA nanosheet at 2nm? A patent-backed technical breakdown of channel geometry, SRAM design, and CFET roadmaps.
Article | Report A deep-dive patent landscape of implantable neural interface technology in 2026: electrode materials, wireless power, closed-loop stimulation, and BCI architectures.
Article | Report How complement alternative pathway inhibitors—ASOs, gene therapy, antibodies, and proteases—are reshaping treatment of geographic atrophy and C3 glomerulopathy.
Article | Report BTK inhibitors are reshaping CNS lymphoma and neuroinflammation treatment. Explore the patent pipeline, resistance mechanisms, and combination strategies in this deep-dive analysis.
Article | Report How RNAi, CRISPR base editing, and LNP delivery are reshaping liver-targeted gene silencing for NASH, HBV, TTR amyloidosis, and dyslipidemia. Patent landscape analysis.
Article | Report GCase activation, Rab1a microautophagy, LRRK2 inhibitors, PINK1/Parkin mitophagy, and gene therapy: a patent-driven analysis of the PD lysosomal-autophagy pipeline.
Article | Report How GLP-1 mono, dual, and triple agonist strategies are reshaping the NASH drug pipeline — patent signals, key assignees, and emerging combination approaches.
Article | Report PROTACs, ASOs, and immunotherapy approaches for tau clearance in Alzheimer's and PSP: phosphoepitope antibodies, peptide vaccines, degraders, and biomarker-guided sequencing.
Article | Report KRAS mutations drive up to 95% of pancreatic and ~45% of colorectal cancers. Explore the patent landscape, inhibitor strategies, and emerging combination approaches.
Article | Report How antisense oligonucleotides, gene therapy, C5aR antagonists, and fusion proteins are reshaping the complement-targeting therapy landscape in GA and C3G.